Observational studyMedicine2025
Application of 11C-CHO in the imaging of cerebral alveolar echinococcosis: A prospective study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Alveolar Echinococcosis in the Early 2020s: A Systematic Review.Pathogens (Basel, Switzerland) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
11C-acetylcholine (11C-CHO) is a positron emission tomography (PET) radiotracer that has been utilized in the diagnosis and treatment of prostate, esophageal, and lung cancers. This preliminary study aimed to assess the feasibility of using 11C-CHO PET/computed tomography (CT) for imaging cerebral alveolar echinococcosis (CAE). In a prospective single-center study, patients with CAE underwent 18F-fludeoxyglucose (18F-FDG) and 11C-CHO PET/CT imaging. The number and location of lesions detected by the 2 tracers were compared, along with determining the maximum standard uptake value (SUVmax) of the lesions and the SUVmax values of the lesions/contralateral normal brain tissue (T/NT values). A total of 35 lesions (mean 4.3 lesions) in 8 CAE patients were imaged using both 18F-FDG and 11C-CHO PET/CT. The findings demonstrated that 11C-CHO PET/CT successfully detected all 35 lesions, achieving a 100% accuracy rate. This contrasted with the performance of 18F-FDG PET/CT, which only identified 24 lesions, resulting in an accuracy rate of 68.57%. Quantitative analysis further indicated that the SUVmax for 11C-CHO PET/CT averaged 3.13±0.93, compared to 9.35±2.84 for 18F-FDG PET/CT. The results of this study highlight the potential of 11C-CHO PET/CT as a novel imaging technique for CAE. In comparison to conventional 18F-FDG PET/CT, 11C-CHO PET/CT demonstrates superior accuracy in lesion detection, suggesting enhanced diagnostic capabilities and potential improvements in patient follow-up. Moving forward, conducting additional clinical studies will be crucial to corroborate and expand upon these promising findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.